Kornimate/medical-research-clean huggingface dataset:
auto-acusar - effects of acupuncture on the autonomic nervous system in seasonal allergic rhinitis patients

Conditions: Seasonal Allergic Rhinitis

Summary: there is inconclusive evidence whether acupuncture treatment is effective in the treatment of seasonal allergic rhinitis (sar). furthermore, the underlying mechanisms of acupuncture in sar are only poorly understood. it was hypothesised that the therapeutic mechanism of acupuncture is related to changes in autonomic function. auto-acusar is a sub-study of the dfg-funded three-arm randomized controlled trial acusar trial investigating the efficacy of acupuncture vs. sham acupuncture vs. rescue medication in sar. the aim of auto-acusar was to investigate short and long-term effects of acupuncture vs. sham acupuncture on autonomic function in a sub-group of acusar patients. baseline values were compared to data from matched healthy controls.

in auto-acusar a subsample of acusar patients from acupuncture or sham acupuncture groups were included. tests of autonomic functions included measurement of heart rate variability during paced breathing, blood pressure, heart rate and salivary alpha amylase response to a cold pressure test (cpt) and cortisol awakening response before the first and the last of twelve treatment sessions. healthy matched controls underwent the same measurement once only

Eligibility criteria:
inclusion criteria: * female or male patients (aged 16-45 years) with seasonal allergic rhinitis, clinically positive and test positive (skin-prick test and/or rast) to grass and birch pollen * patients with \>2 years of moderate to severe sar * positive skin-prick test and/or rast (at least class 2) results * visual analogue scale \>40mm and \<80 mm for sar symptoms during the past year * patients must be able to complete a diary for self-evaluation of symptoms and recording use of anti-symptomatic medication * use of, or indication for, oral antihistamines as anti-allergic medication * written informed consent exclusion criteria: * perennial sar or other types of chronic rhinitis * allergic asthma and/or moderate to severe atopic dermatitis * active tuberculosis * auto-immune disorders * severe chronic inflammatory diseases * history of anaphylactic reactions * hypersensitivity to rescue medication or related drugs used in study related drugs * specific immunotherapy \>3 years * simultaneous participation in other clinical trials * serious acute or chronic organic disease or mental disorder * pregnancy or breast feeding * allergy desensitisation therapy (current, during the past two years, or planned in the next two years) * blood coagulation disorder and/or current use of anticoagulants * previous acupuncture treatment for sar * any complementary and alternative medicine treatment at the moment, in the last three months or planned in the next two years * intake of beta-blocker medication * use of pacemaker

Keywords: acupuncture autonomic nervous system seasonal allergic rhinitis
sbrt+tace+sorafenib vs sorafenib in the treatment of uhcc with pvtt

Conditions: Unresectable Hepatocellular Carcinoma; Portal Vein Thrombosis

Summary: to evaluate and compare the efficacy and safety of sbrt sequential tace combined with sorafenib versus sorafenib alone in the treatment of unreactable hcc with pvtt.

hcc patients classified as bclc stage c present with pvtt, and the recommended first-line treatment is systemic therapy with sorafenib according to updated barcelona clinical liver cancer (bclc) treatment algorithms.however, recent data from observational studies suggest that the combination of tace and sbrt would be as effective as sorafenib.

Eligibility criteria:
inclusion criteria: * age \>18 years * child-pugh score ≤ 7 * performance status: ecog score ≤ 2 * hcc diagnosed by biopsy or by the noninvasive criteria of the chinese liver cancer guideline 2017 * the primary hcc being unresectable (bclc c stage/ cnlc ⅲa-b) according to nccn guideline * no previous therapy for hcc * at least one measurable target lesion according to recist 1.1 * adequate hematopoietic function: hemoglobin ≥ 8.5 g/dl; absolute neutrophil count ≥ 750/mm3; platelet count ≥ 50,000/mm3 * serum total bilirubin ≤ 2 x uln * aspartate aminotransferase (ast) and alanine aminotransferase ≤ 10 x uln * creatinine ≤ 1.5 x uln * no plan for pregnancy or breast feeding. active contraception. * willing to give informed consent exclusion criteria: * prior history to or exposure of transarterial chemoembolization, external beam radiation to liver, or sorafenib * complete obstruction of hepatic outflow * uncontrolled ascites of hepatic encephalopathy * prior liver transplantation * positive for human immunodeficiency virus (hiv) * active gastric or duodenal ulcer * other uncontrolled comorbidities or malignancy * inability to give informed consent

Keywords: hepatocellular carcinoma,portal vein tumor thrombus radiation ,sorafenib
the effect of stellate ganglion block on intracranial pressure predicted by ultrasonographic assessment of optic nerve sheath diameter

Conditions: Pain; Intracranial Pressure

Summary: the stellate ganglion block increase cerebral blood flow, as the consequence of that, it has the potential to cause an increase of intracranial pressure (icp). previous studies have proposed that ultrasonographic measurements of the optic nerve sheath diameter (onsd) correlate with signs of increased icp. therefore, this study is aim to confirm the increased icp by ultrasonographic measurement of onsd after the stellate ganglion block.


Eligibility criteria:
inclusion criteria: * adult patients (20-70 years of age) * who were scheduled to receive stellate ganglion block at our pain management clinic exclusion criteria: * patients with previous history of neurologic disease, carotid disease, transient ischemic attack, ocular disease and ocular surgery * patients with coagulation disorder * patients with severe obesity * patients with severe cardiovascular or pulmonary disease * patients with cognitive deficits or psychiatric illness

Keywords: stellate ganglion block
the impact of video information on preoperative anxiety in interventional cardiology patients.

Conditions: Coronary Artery Disease; Atrial Fibrillation; Atrial Flutter

Summary: this study evaluates the impact of educative videos on anxiety for patients entering hospital for cardiology intervention


Eligibility criteria:
inclusion criteria: * patient entering hospitalisation in cardiology department for a cardiology intervention. exclusion criteria: * protected person.
alternative therapies prescribed by pharmacists and herbalists

Conditions: Prescription Drug Problems

Summary: the cross-sectional study will recruit herbalists and pharmacists at their workplaces (herbal shops and pharmacies); where they will be asked their advice about a patient suffering from a potentially malignant condition.

the cross-sectional study will recruit herbalists and pharmacists at their workplaces (herbal shops and pharmacies); where they will be asked their advice about a patient suffering from a potentially malignant condition. based on the standardized simulated patient approach, the cross-sectional study was planned in which an individual interacts with the interviewee according to a previously prepared script.

Eligibility criteria:
inclusion criteria: * working as herbalist, pharmacist or assistant pharmacist exclusion criteria: -

Keywords: oral potentially malignant lesion
adults with attention deficit hyperactivity disorder (adhd): validation of a clinical interview and screening instruments in french

Conditions: Attention Deficit Hyperactivity Disorder

Summary: adhd is a neurodevelopmental disorder that affects about 5% of school-age children and 3.5% of adults worldwide. this condition is under-recognised in france and other european countries and, therefore, under-diagnosed. as part of the european network for adult adhd, the investigators translated into french a structure interview called the diagnostic interview for adult adhd (diva). the investigators also translated rating scales such as the asrs and the wurs. validation studies are rare in france. the aim of this study is to include two groups of 50 adults whether they have or not adhd with respect of diagnostic and statistical manual - revision 4(dsm-iv) criteria as implemented in the diva (i.e. actual at adulthood and past in childhood). subjects have to fill out a booklet of questionnaires including the who's adult adhd symptom rating scale (asrs) (screening tool for actual diagnosis) and the wender utah rating scale (wurs, a screening tool for adhd in childhood with respect of the utah criteria). the investigator will be able to compare the actual criteria for adhd between the asrs and the diva, and the past criteria for adhd between the wurs and the diva. finally, an estimate of the prevalence of adhd in adults will be computed.


Eligibility criteria:
inclusion criteria: * authorization to use the data signed social security affiliation exclusion criteria: * patient presenting a known neurological or psychiatric disorder, or a deficit intellectual because the attentional disorders(confusions), the psychomotor excitement and the impulsiveness can be symptoms inherent to the other pathologies neurological and\\or psychiatric.

Keywords: touble deficit attention hyperactivity touble deficit attention with hyperactivity
comparison of two web-based education/support programs for partner caregivers of people with spinal cord injury

Conditions: Spinal Cord Injuries; Spinal Cord Diseases

Summary: the purpose of this research study is to compare the effect of two different types of education and support programs for partner caregivers of people with spinal cord injury (sci).

sci particularly affects partners (spouses or other types of significant others), as they face changes in relationship dynamics and identity as they take on a caregiver role. the purpose of this research study is to compare the effect of two different types of education and support programs for partner caregivers of people with spinal cord injury (sci).

Eligibility criteria:
inclusion criteria: * at least 18 years old * fluent in english (reading and writing) * romanic partner of a person with sci (regardless of martial status) for at least one year prior to injury * live in a private residence with their partner with sci * partner is at least 3 months post discharge from inpatient rehabilitation * at least 6 months since their partner's injury * provide care to their partner with sci on a daily basis * have access to the internet in a private location exclusion criteria: * participant reports a diagnosis of a schizoaffective disorder, bipolar personality disorder, or severe depression * history of hospitalization for depression treatment

Keywords: caregivers spouse partner caregiver burden spinal cord injury quality of life internet based intervention grief emotions clinical trial
long term effects of multifocal orthokeratology on corneal and choroidal structures in healthy subjects with myopia- a pilot study

Conditions: Myopia

Summary: orthokeratology has the benefit for slowing down myopia progression and enabling unaided vision during the day. to investigate proposed possible changes of conventional and multifocal orthokeratology in the cornea and choroid this study will image both structures with high resolution optical coherence tomographs over a six month period. findings will help to plan larger trials over a longer period of time in adults and teenagers.


Eligibility criteria:
inclusion criteria: * men and women aged over 18 years * myopia defined as between -1d and -6 d with an increase of 0.5d within the last 18months prior to inclusion * prospect orthokeratology contact lens wearers * normal findings in the slit lamp examination, no corneal pathologies exclusion criteria: * participation in a clinical trial in the previous 3 weeks * presence of any abnormalities (such as refractive surgery) preventing reliable measurements as judged by the investigator * current contact lens wearers * pregnancy, planned pregnancy or lactating

Keywords: orthokeratology
intensive stress coping intervention week - a secondary prevention for real world affective disorder patients

Conditions: Affective Disorders; Psychological Stress; Inflammation; Oxidative Stress; Anxiety Disorders; Mood Disorders; Emotions

Summary: this study intents to determine who will benefit from an intensive brief stress coping intervention week (isciw) as secondary prevention for real world affective disorder patients.

affective disorders are associated with a substantial personal and socio-economic burden. this study evaluates an intensive brief stress-coping intervention week (isciw) as feasible follow-up treatment for real world patients who suffer from this highly prevalent and chronic stress-related disorders. stress-associated blood (interleukin-6, homocystein, myeloperoxidase), saliva cortisol and psychosocial screening parameters will be analyzed to determine who will benefit from the isciw. all patients were identified in a preventive medical screening before pre-treatment for at least three month as outpatient and the following inclusion to the follow-up isciw-trial at the health and prevention center, sanatorium hera, vienna, austria. for the three planed groups and interventions see interventions and arms.

Eligibility criteria:
inclusion criteria: * affective or anxiety disorder dsm-iv diagnosis (structured interview, m.i.n.i. international neuropsychiatric interview ) * minimum 3-weeks previous therapeutic treatment as outpatient at the health and prevention center, sanatorium hera, vienna, austria * clinical global impression - severity (cgi-s) score \> 2 points * minimum improvement of 1 cgi-s points as outpatient * written informed consent exclusion criteria: * more than 60 days away sick per year in the last year before intervention * therapy adherence as outpatient at the health and prevention center, sanatorium hera, vienna, austria * work ability index (wai) score \< 25 points * major neurological or cognitive deficits * current psychotic symptoms * current or previous dsm-iv diagnosis of substance dependence, except for nicotine or current substance abuse * failures to comply with the study protocol or to follow the instructions of the study team * currently requested application for retirement * middle to high suicidal tendency in the m.i.n.i.-examination
urine exosomes to identify biomarkers for ln

Conditions: Lupus Nephritis

Summary: urine exosomes will be extracted from patients with lupus nephritis, healthy controls, and patients with systemic lupus erythematosus without lupus nephritis. transcriptome and/or metabonomics sequencing of exosomes will be performed to screen for molecules in the urine exosomes of patients with lupus nephritis that are significantly different from those of the other groups.

lupus nephritis is one of the most common complications of sle, and its severity is closely related to the prognosis of sle. the gold standard for diagnosing lupus nephritis depends on the pathological results of a kidney biopsy, which is invasive and may cause some damage to the patient. exosomes exist in almost all types of body fluids such as serum, urine and cerebrospinal fluid, and contain a variety of genetic materials and proteins secreted by cells, such as mirna, lnrna, cirrna and metabolites, etc., which are potential substances that can be used as biomarkers of diseases discovered in recent years. urine exosomes are easy to obtain and have no impact on patients' health, making them suitable for study as disease biomarkers for lupus nephritis. in this study, urine exosomes will be extracted from patients with lupus nephritis, healthy controls, and patients with systemic lupus erythematosus without lupus nephritis. transcriptome and/or metabonomics sequencing of exosomes will be performed to screen for molecules in the urine exosomes of patients with lupus nephritis that are significantly different from those of the other groups.

Eligibility criteria:
inclusion criteria: * no history of chronic or serious diseases such as cardiovascular disease, liver disease, kidney disease, respiratory disease, blood disease, lymphatic disease, endocrine disease, immune disease, mental disease, neuromuscular disease, gastrointestinal system disease, etc. * general health condition is good; * vital signs examination, physical examination, clinical laboratory examination (blood routine, urine routine, blood biochemical examination, coagulation function examination), electrocardiogram, and the results show normal or abnormal without clinical significance exclusion criteria: * other rheumatic immune disease; * abnormal liver and kidney function; * acute and chronic infectious diseases.
study of imatinib-combined chemotherapy for bcr-abl-positive acute lymphoblastic leukemia (all)

Conditions: Acute Lymphoblastic Leukemia

Summary: the purpose of this study is to determine the clinical efficacy and safety of imatinib-combined chemotherapy on newly diagnosed bcr-abl-positive all.

philadelphia chromosome (ph) is a translocation abnormality leading to the formation of the bcr-abl gene rearrangement. this genetic abnormality occurs in up to 30% of adult acute lymphoblastic leukemia (all), and its presence is known to be the most adverse prognostic factor for all. because long-term survival cannot be achieved by conventional chemotherapy alone, there is a clear medical need for alternative treatment approaches. imatinib is a potent selective inhibitor of the bcr-abl protein kinase, and it has been reported that single-agent imatinib induced response in a substantial proportion of ph-positive all (ph+all) patients, but that the response was not durable. the japan adult leukemia study group (jalsg) has therefore started a phase 2 study designed to evaluate the clinical effect of imatinib-combined chemotherapy on newly diagnosed bcr-abl-positive all.

Eligibility criteria:
inclusion criteria: * previously untreated bcr-abl-positive all * age between 15 and 64 years * performance status between 0 and 3 (ecog criteria) * adequate functioning of the liver (serum bilirubin level \< 2.0 mg/dl), kidneys (serum creatinine level \< 2.0 mg/dl), and heart (left ventricular ejection fraction greater than 50% and no severe abnormalities detected on electrocardiograms and echocardiographs) * written informed consent to participate in the trial exclusion criteria: * uncontrolled active infection * another severe and/or life-threatening disease * positive for hiv antibody and/or hepatitis b surface (hbs) antigen tests * another primary malignancy which is clinically active and/or requires medical interventions * pregnant and/or lactating women * past history of renal failure

Keywords: acute lymphoblastic leukemia bcr-abl philadelphia-chromosome newly diagnosed
assessing cerebrovascular reactivity based on cerebral oximetry: a pilot study

Conditions: Hypoxia-Ischemia, Brain; Signs and Symptoms

Summary: the brain is such a metabolically active organ that it consumes about 20% of oxygen burned every minute by an average adult even though it only contributes about 2% of the body weight. as a result, the brain produces a disproportionately high amount of co2 every minute in comparison with the rest of the body.

the researcher can use diffuse optical spectroscopy imaging, cerebral non-invasive oximetry instrument, to determine cerebrovascular reactivity during surgery procedure. specifically, the cerebral tissue o2 saturation can measure by diffuse optical spectroscopy imaging can use for cerebral blood flow in the evaluation of cerebrovascular reactivity. adequate brain perfusion is critical not only to supply oxygen and nutrients but also to wash out metabolic end products including co2. blood flow depends on perfusion pressure and vascular bed resistance. it is well known that multiple physiological and pathological factors affect cerebral vasculature, and the resistance to blood flow. the cerebrovascular responsiveness to those factors determines how well the brain can maintain and adjust its perfusion.

Eligibility criteria:
inclusion criteria: 1. male or female 20 years of age and older 2. female non-pregnant 3. subject scheduled for elective surgery under general anesthesia with intubation. 4. subject who is able to give informed consent. exclusion criteria: 1. less than 20 years old of age 2. pregnant woman 3. subjects currently diagnosed with severe hypertension, myocardial ischemic disease, symptomatic valvular disease(s), symptomatic arrhythmia, uncompensated congestive heart failure, intracranial aneurysm.
study to analyze the aerobic performance efficacy of chronic intake with a β-alanine supplement in recreational cyclists

Conditions: Beta Alanine Supplementation

Summary: randomized, controlled, double-blind, double-blind clinical trial, with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) and single-center, to measure the efficacy of a sustained release beta alanine on the aerobic performance efficacy in recreational cyclist

subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned). the product to be consumed is beta alanine. participants will consume the product for 30 days. they will have to take 4 intakes every three hours, being the first intake two hours after waking up. the study subjects will have to make 2 visits to the laboratory. at the first and last visit, their aerobic performance will be evaluated by an incremental test to exhaustion with gas analysis.

Eligibility criteria:
inclusion criteria: * male cyclists with more than two years of cycling experience. * perform tests without fatigue. * road bike training at least twice a week. exclusion criteria: * participants with chronic illness. * have a long-term injury that prevents you from training in the previous month. * inability to understand informed consent. * have consumed beta alanine in the three years prior to the start of the study. * consumption of other supplements that may alter performance.

Keywords: aerobic performance beta alanine supplementation